Showing results (11-20 of 115) with videos related to
Sort By:
Pageof 12
Expert Reviews in Molecular Medicine|July 2, 2008
P21 and p27: roles in carcinogenesis and drug resistanceAbde M Abukhdeir, Ben Ho ParkCurrent Opinion in Oncology|December 21, 2004
Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoterKurtis E Bachman, Ben Ho ParkJournal of the National Comprehensive Cancer Network : JNCCN|June 8, 2013
The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancerJosh Lauring, Ben Ho Park, Antonio C WolffClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2022
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid TumorsSarah C Reed, Sarah Croessmann, Ben Ho ParkBreast Cancer Research : BCR|February 22, 2013
Needles in a haystack: finding recurrent genomic changes in breast cancerJustin Cidado, Julia A Beaver, Ben Ho ParkThe Journal of Pathology|October 12, 2013
Somatic alterations as the basis for resistance to targeted therapiesBrian G Blair, Alberto Bardelli, Ben Ho ParkMethods in Molecular Biology (Clifton, N.J.)|May 3, 2018
Detection of Cancer DNA in Early Stage and Metastatic Breast Cancer PatientsArielle J Medford, Riaz N Gillani, Ben Ho ParkAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation SequencingAaron S Mansfield, Ben Ho Park, Michael P MullaneCurrent Cancer Drug Targets|December 17, 2008
The PIK3CA gene as a mutated target for cancer therapyJohn P Gustin, David P Cosgrove, Ben Ho ParkCancer Research|June 5, 2007
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell deathMeihua Sui, Yi Huang, Ben Ho Park, et al.Pageof 12